/RAPP

Rapport Therapeutics Inc

RAPP

$49.33USD↑+2.26%+1.09 today

MARKET CAP

2.4B

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$47 – $50

52W RANGE

$14

$50

AI Summary

Stalk

StalkMedium

RAPP remains in a Stage 2 advance with a medium-term bullish bias confirmed by clear higher highs and higher lows, but extreme overbought conditions counsel caution. Price is pulling back into its rising short-term EMAs, creating a shallow pullback zone within the uptrend. Execution is best deferred until clear acceptance above the EMAs, in line with the Momentum + EPS strategy favoring trend continuation on shallow pullbacks.

↑RAP-219 and related pipeline target neurological, chronic pain, and hearing disorders.
↑Liquidity of $63.6M cash plus $372.5M short-term investments funds operations.
↓H1 2026 net loss of $76.5M expands accumulated deficit to $311.7M.

Full analysis →

Buying

6

institutions

Selling

4

institutions

New Positions

2

this quarter

Filing Period

Q2 2026

latest 13-F

13-F Holdings

Institution↕	Action↕	Shares Held↕	Value↓	Change↕	Chg %↕	Weight↕
BI Blackrock, Inc. Q2 2026	BUY	2.70 M	112.50 M	+193.83 K	+43.5%	0.00%
PA Perceptive Advisors LLC Q2 2026	SELL	773.34 K	32.23 M	+-574.50 K	-23.6%	0.48%
TR T. Rowe Price Investment Management, Inc. Q2 2026	SELL	393.20 K	16.39 M	+-227.40 K	-15.6%	0.01%
MM Millennium Management LLC Q2 2026	SELL	154.91 K	6.46 M	+-164.64 K	-35.4%	0.00%
WP Woodline Partners LP Q2 2026	BUYNEW	97.54 K	4.06 M	+97.54 K	+0.0%	0.01%
CA Citadel Advisors LLC Q2 2026	BUYNEW	82.44 K	3.44 M	+82.44 K	+0.0%	0.00%
AC Aqr Capital Management LLC Q2 2026	BUY	26.45 K	1.10 M	+944.00	+38.1%	0.00%
JH Janus Henderson Group Plc Q1 2026	BUY	27.60 K	865.54 K	+13.80 K	+106.7%	0.00%
JC Jpmorgan Chase & Co Q2 2026	BUY	16.56 K	669.02 K	+718.00	+52.5%	0.00%
RT Renaissance Technologies LLC Q2 2026	SELL	0.00	0.00	+-9.70 K	-100.0%	0.00%